​

Alector Stock (NASDAQ:ALEC)

ForecastRevenueOwnershipFinancialsChartTranscripts
Alector by TradingView

Previous Close

$1.49

52W Range

$1.09 - $3.40

50D Avg

$1.81

200D Avg

$1.92

Market Cap

$164.32M

Avg Vol (3M)

$719.93K

Beta

0.60

Div Yield

-

ALEC Company Profile

Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies. Its treatment targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

103

IPO Date

Feb 07, 2019

Website

ALEC Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/ServiceDec 21
Phase Three License$173.40M

Fiscal year ends in Dec 25 | Currency in USD

ALEC Financial Summary

Dec 25Dec 24Dec 23
Revenue$21.05M$100.56M$97.06M
Operating Income$-156.01M$-145.00M$-151.74M
Net Income$-142.93M$-119.05M$-130.39M
EBITDA$-156.01M$-136.16M$-142.89M
Basic EPS$-1.39$-1.23$-1.56
Diluted EPS$-1.39$-1.23$-1.56

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts

Q2 25Aug 07, 25 | 4:30 PM
Q4 24Feb 26, 25 | 4:30 PM
Q2 24Aug 07, 24 | 4:30 PM

Peer Comparison

TickerCompany
IRDOpus Genetics, Inc.
CRBPCorbus Pharmaceuticals Holdings, Inc.
MOLNMolecular Partners AG
NKTXNkarta, Inc.
FATEFate Therapeutics, Inc.
VORVor Biopharma Inc.
ABOSAcumen Pharmaceuticals, Inc.
PEPGPepGen Inc.
SAVACassava Sciences, Inc.